Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/33632
Title: Outcomes out to 12 months after sequential use of high-dose tofacitinib following infliximab in acute severe ulcerative colitis.
Austin Authors: Eqbal, Ali;Hilley, Patrick ;Choy, Matthew C ;Srinivasan, Ashish ;De Cruz, Peter P 
Affiliation: Gastroenterology and Hepatology
Medicine (University of Melbourne)
Department of Medicine, Austin Academic Centre, University of Melbourne, Melbourne, Australia.
Issue Date: Aug-2023
Publication information: Internal Medicine Journal 2023-08; 53(8)
Abstract: Acute severe colitis (ASUC) remains a significant cause of morbidity in up to 25% of patients with ulcerative colitis during their disease course. We present the outcomes out to 12 months following the use of high-dose tofacitinib, 10 mg three times daily (TDS), in patients with steroid and infliximab refractory ASUC. A total of 11 patients with ASUC who were treated with high-dose tofacitinib after failing sequential infliximab therapy between 2019 and 2021 were identified at an Australian tertiary centre. Ten of 11 patients demonstrated clinical and biochemical response to treatment during admission. Two of 11 patients required colectomy, one during the index admission and the other during re-admission 10 days after the index presentation. Nine of the initial responders had a median Mayo score of 1 (IQR 0-4) at both 6 and 12 months, and all remained colectomy-free out to 12 months. Neither venous thromboembolic events nor major infective complications were observed. Tofacitinib may be a safe and effective induction and maintenance agent in the treatment of steroid and infliximab refractory ASUC. Prospective studies with long-term follow-up are required to explore the use of tofacitinib in ASUC before it can be routinely recommended as salvage therapy.
URI: https://ahro.austin.org.au/austinjspui/handle/1/33632
DOI: 10.1111/imj.16192
ORCID: 0000-0001-5448-5873
Journal: Internal Medicine Journal
Start page: 1497
End page: 1500
PubMed URL: 37599224
ISSN: 1445-5994
Type: Journal Article
Subjects: acute severe colitis
sequential therapy
tofacitinib
Colitis, Ulcerative/drug therapy
Infliximab/therapeutic use
Appears in Collections:Journal articles

Show full item record

Page view(s)

42
checked on Nov 3, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.